-
Triple-negative Breast Cancer (TNBC) Heavy News! The first TROP-2 targeted antibody-drug-conjugate therapy Trodelvy is available in the United States!
Time of Update: 2020-05-05
05 May 2020 / Biovalley BIOON/--Immunomedic is a pioneer of next-generation antibody drug conjugate (ADC) technology dedicated to helping cancer patients change their lives At the heart of its prop
-
Mol Ther: Breakthrough! Research and development of new methods for the treatment of liver cancer
Time of Update: 2020-05-04
May 4, 2020 / Biovalley BIOON /-- In the latest issue of Molecular Therapy, researchers at Skoltech and the Massachusetts Institute of Technology have published a new combination of therapies to tr
-
Nature Sub-journal: New drug successfully stops cancer metastasis!
Time of Update: 2020-05-02
May 2, 2020 / Bio-Valley BIOON/- Researchers at the Francis Crick Institute have discovered a drug that is patient-tolerant and prevents cancer from recurring in mice One of the biggest challenges
-
Heavy immunotherapy drug Tai Sanqi ® China to break through 30 years of treatment for small cell lung cancer
Time of Update: 2020-04-30
on April 29, , Roche's cancer immunoinnovation drug Tesanchi ® ("Tecentriq®, generic name: Atlizumab) combined chemotherapy for first-line treatment of wide-term small cell lung cancer was officially
-
Tumor immunotherapy upgrade! Mercadon Keytruda's 6-week administration program was approved by the U.S. FDA, and the efficacy is comparable to the 3-week program!
Time of Update: 2020-04-30
April 30, 2020 / PRNewswire BIOON/ -- Merck and Co has announced that the U.S Food and Drug Administration ( FDA ) has approved the anti-PD-1 therapy Keytruda (Creeda, GENERAL Motors) Name: pembrol
-
Heavy news! Russian local research and development of anti-PD-1 therapy Forteca approved for listing, Shanghai Pharma and BIOCAD joint venture to introduce Greater China!
Time of Update: 2020-04-30
April 30, 2020 / Bio-Valley BIOON/ -- Russian BIOCAD Biopharmaceutical sino has announced that the first locally developed PD-1 inhibitor Forteca (INN:prolgolimab) has been approved by the Russian
-
Tumor immunotherapy upgrade! Mercadon announces the first clinical results: Keytruda 6-week medication program, the efficacy is comparable to the 3-week program!
Time of Update: 2020-04-28
April 27, 2020 /pr. bioON/ BioValley BIOON/ -- Merck and Co recently released medium-term data on the anti-PD-1 therapy Keytruda (Creeda, generic name: pembrolizumab, Pablo zumab, Pablo zumab) tre
-
Lung cancer! Sanofi/Regenerative Dollar Libtayo single-drug first-line treatment PD-L1 high expression lung cancer stage III significantly prolongs survival, early termination!
Time of Update: 2020-04-28
April 27, 2020 / prnewswire BIOON/ -- Sanofi and partner Regeneron recently announced that a Phase III trial evaluating anti-PD-1 therapy Libtayo (cemiplimab) for the treatment of non-small cell l
-
The administration is reduced from 3 hours to 5 minutes! Johnson and Johnson's heavy CD38 target anti-cancer drug Darzalex (mega-®) subcutaneous injection preparation Japan applies for listing!
Time of Update: 2020-04-27
April 27, 2020 / Biovalley BIOON/ -- Jansen Pharmaceuticals Inc., part of Johnson and Johnson (JNJ), recently submitted a new drug application (NDA) to the Ministry of Health, Labor and Welfare (M
-
First-line treatment in line with stem cell transplantation of the new diagnosis of multiple myeloma! Johnson and Johnson Darzalex (Mega®) and RVd solution demonstrate severance!
Time of Update: 2020-04-26
April 26, 2020 / Biovalley BIOON/ -- For new patients with multiple myeloma (NDMM) who meet the conditions for transplantation, self- stem cell transplantation (ASCT) is a standard first-line the
-
B cell tumor target new drug! MEI/Concord Kirin cooperates to develop PI3K inhibitor MEI-401 to treat total remission rate of 75-100% for class 3 tumors
Time of Update: 2020-04-26
April 26, 2020 / PRNewswire BIOON/ -- MEI Pharma is a late-stage, clinical biopharmaceutical company dedicated to developing innovative therapies for cancer treatment Recently, the company announce
-
PD-(L)1 field GSK shines! Dostarlimab treatment for late-stage or recurrent endometrial cancer shows strong efficacy, with a total remission rate of 42%!
Time of Update: 2020-04-25
April 25, 2020 / Bio-Valley BIOON/ -- GlaxoSmithKline (GSK) recently released the latest analysis of the anti-PD-1 therapy dotarlimab (formerly known as TSR-042) Phase I/II clinical study GARNET
-
Tumor immunotherapy upgrade! Mercadon Keytruda's 6-week resubmission of the drug program covers all adult indications!
Time of Update: 2020-04-24
April 24, 2020 / Biovalley BIOON/ -- Merck and Co recently announced that it has resubmitted its application for a license for complementary biological products to the U.S Food and Drug Administrat
-
Triple-negative Breast Cancer (TNBC) Heavy News! The first TROP-2 targeted antibody-drug conjugate therapy, Trodelvy, was accelerated by the FDA!
Time of Update: 2020-04-23
April 23, 2020 /prnewswire BIOON/--Immunomedic is a pioneer of next-generation antibody drug conjugate (ADC) technology dedicated to helping cancer patients change their lives At the heart of its p
-
Nature: The endometrial begins to produce cancer-causing mutations early in life!
Time of Update: 2020-04-23
April 23, 2020 /PRNewswire/ -- Understanding how normal tissues cause cancer is critical to improving prevention and early detection of this deadly disease Over the past two decades, the genome mapp
-
Malignant pleural mesothelioma (MPM) significant progress! BMS immune combination Opdivo-Yervoy first-line therapy Phase III clinical significantly extended the total survival!
Time of Update: 2020-04-21
April 21, 2020 / BioValley BIOON / -- Baishi Meishi Guibao (BMS) recently announced the evaluation of anti-PD-1 therapy Opdivo (Odivo, generic name: nivolumab, Navulieu) The phase III CheckMate-743
-
Advanced kidney cancer "targeting and immune" first-line treatment! The BMS/Exelixis combination therapy Cabometyx and Opdivo III clinical success!
Time of Update: 2020-04-21
April 21, 2020 / pr. BIOON/ -- Bjour Mei squibb (BMS) and Exelixi Co., Inc recently jointly announced the evaluation of anti-PD-1 therapy Opdivo (Odivo, generic name: niumvol Ab, Navuriu monoantige
-
Domestic PD-1 therapy! Baiji Shenzhou Baizean ® first-line treatment of advanced squamous lung cancer (NSCLC) new indications application by the State Drug Administration to accept!
Time of Update: 2020-04-21
April 21, 2020 / Biovalley BIOON / -- BeiGene announced recently that the National Drug Administration (NMPA) Drug Review Center (CDE) has accepted its anti-PD The -1 antibody drug Perze®zumab (ti
-
Inter J Cancer: Self-binding! Trigger melanoma suicide switch to fight cancer!
Time of Update: 2020-04-20
April 20, 2020 / BIOON/ -- Scientists at the Centennial Institute in Sydney, Australia, have reported a new strategy to fight melanoma melanoma is the most dangerous form of skin cancer, killing
-
Nature: Beware! Genetic mutation increases risk of brain tumors in children
Time of Update: 2020-04-16
April 16, 2020 /prnewswire 2020 / Bio-Valley BIOON / -- Researchers at St Jude Children's Research Hospital, the European Molecular Biology Laboratory and the German Cancer Research Center have ide
